Figure 7.

NHS-muIL12/avelumab combination treatment had a synergistic antitumor effect and induced long-term protective immunity in EMT-6 tumor-bearing mice. (A–C) EMT-6 tumor-bearing BALB/c mice were treated with: (i) isotype control (200 µg), (ii) NHS-muIL12 (2 µg), (iii) NHS-muIL12 (10 µg), (iv) avelumab (200 µg), (v) NHS-muIL12 (2 µg) + avelumab (200 µg), or (vi) NHS-muIL12 (10 µg) + avelumab (200 µg). (A) Average tumor volumes. (B) Individual tumor volumes. P values were calculated by 2-way ANOVA followed by Bonferroni’s post-test. (C) Kaplan-Meier survival curve and proportion of tumor clearance. (D) Mice in complete remission and naive BALB/c mice were challenged with EMT-6 or 4T1 cells. Error bars represent SEM. Reproduced with permission from Xu C, Zhang Y, Rolfe PA, Hernàndez VM, Guzman W, Kradjian G, Marelli B, Qin G, Qi J, Wang H,Yu H, Tighe R, Lo K-M, English JM, Radvanyi L, Lan Y. Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models. Clin Cancer Res. 2017;23(19):5869–5880.¹⁰ Copyright © 2017, American Association for Cancer Research. All rights reserved.